

Massimo Offidani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8497596/publications.pdf>

Version: 2024-02-01

143
papers

11,744
citations

57758

44
h-index

28297

105
g-index

144
all docs

144
docs citations

144
times ranked

8890
citing authors

#	ARTICLE	IF	CITATIONS
1	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	1.6	1,525
2	Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. <i>Lancet</i> , The, 2010, 376, 2075-2085.	13.7	770
3	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 27-38.	10.7	723
4	Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 895-905.	27.0	683
5	The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. <i>Haematologica</i> , 2006, 91, 1068-75.	3.5	650
6	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	1.4	586
7	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 5101-5109.	1.6	400
8	Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 986-993.	1.6	302
9	Thalidomide for treatment of multiple myeloma: 10 years later. <i>Blood</i> , 2008, 111, 3968-3977.	1.4	294
10	Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1617-1629.	10.7	289
11	Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. <i>Haematologica</i> , 2010, 95, 644-650.	3.5	273
12	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 333-342.	10.7	256
13	Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. <i>Blood</i> , 2011, 117, 3025-3031.	1.4	247
14	Autologous haematopoietic stem-cell transplantation versus bortezomib+mephalan+prednisone, with or without bortezomib+lenalidomide+dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Haematology</i> , the, 2020, 7, e456-e468.	4.6	244
15	Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. <i>Blood</i> , 2016, 127, 2833-2840.	1.4	207
16	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. <i>Journal of Clinical Oncology</i> , 2014, 32, 634-640.	1.6	198
17	Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. <i>Haematologica</i> , 2013, 98, 980-987.	3.5	193
18	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2019, 393, 253-264.	13.7	187

#	ARTICLE	IF	CITATIONS
19	Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients. <i>Journal of Clinical Oncology</i> , 2010, 28, 800-807.	1.6	166
20	Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. <i>Blood</i> , 2014, 124, 63-69.	1.4	126
21	<i>Pneumocystis carinii</i> pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. <i>British Journal of Haematology</i> , 2002, 117, 379-386.	2.5	123
22	Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1705-1720.	10.7	120
23	Invasive Aspergillosis in Patients with Acute Leukemia: Update on Morbidity and Mortality-SEIFEM-C Report. <i>Clinical Infectious Diseases</i> , 2007, 44, 1524-1525.	5.8	102
24	Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients. <i>Cancer</i> , 2012, 118, 1574-1584.	4.1	102
25	Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. <i>Blood</i> , 2006, 108, 2159-2164.	1.4	101
26	Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 3130-3142.	7.0	86
27	The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type 2. <i>International Journal of Cancer</i> , 2014, 134, 2534-2546.	5.1	86
28	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). <i>Leukemia</i> , 2018, 32, 1697-1712.	7.2	83
29	Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. <i>European Journal of Haematology</i> , 2005, 75, 136-145.	2.2	79
30	Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2016, 127, 1102-1108.	1.4	78
31	Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. <i>European Journal of Haematology</i> , 2010, 84, 223-228.	2.2	77
32	Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. <i>Blood</i> , 2013, 122, 1376-1383.	1.4	74
33	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	7.1	67
34	Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). <i>Haematologica</i> , 2015, 100, 284-292.	3.5	64
35	Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. <i>Haematologica</i> , 2006, 91, 133-6.	3.5	63
36	Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. <i>Oncotarget</i> , 2016, 7, 77543-77557.	1.8	62

#	ARTICLE	IF	CITATIONS
37	Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. <i>American Journal of Hematology</i> , 2013, 88, 16-23.	4.1	60
38	Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. <i>Haematologica</i> , 2007, 92, 686-689.	3.5	56
39	Results of a Multicenter, Controlled, Randomized Clinical Trial Evaluating the Combination of Piperacillin/Tazobactam and Tigecycline in High-Risk Hematologic Patients With Cancer With Febrile Neutropenia. <i>Journal of Clinical Oncology</i> , 2014, 32, 1463-1471.	1.6	55
40	Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. <i>Oncotarget</i> , 2015, 6, 17543-17558.	1.8	55
41	Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2035-2043.	1.6	55
42	Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. <i>Blood</i> , 2006, 108, 3951-3952.	1.4	53
43	Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome. <i>Clinical Cancer Research</i> , 2013, 19, 3247-3258.	7.0	50
44	Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5001-5007.	1.6	46
45	Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. <i>European Journal of Haematology</i> , 2004, 72, 403-409.	2.2	43
46	Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. <i>European Journal of Haematology</i> , 2004, 72, 10-17.	2.2	43
47	Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1722-1727.	1.3	43
48	An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma. <i>OncoTargets and Therapy</i> , 2014, 7, 1793.	2.0	43
49	Ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1287-1298.	4.1	42
50	Assessment of Vulnerability Measures and Their Effect on Survival in a Real-Life Population of Multiple Myeloma Patients Registered at Marche Region Multiple Myeloma Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 423-432.	0.4	41
51	Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3027-3036.	1.4	40
52	Thalidomide+dexamethasone versus Interferon- α +dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study. <i>British Journal of Haematology</i> , 2009, 144, 653-659.	2.5	37
53	Long-term hematologic reconstitution after autologous peripheral blood progenitor cell transplantation: a comparison between controlled-rate freezing and uncontrolled-rate freezing at -80°C . <i>Transfusion</i> , 2003, 43, 42-49.	1.6	35
54	Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. <i>Blood Reviews</i> , 2019, 34, 84-94.	5.7	35

#	ARTICLE	IF	CITATIONS
55	Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. <i>Blood</i> , 2011, 118, 5759-5766.	1.4	34
56	The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). <i>Oncotarget</i> , 2016, 7, 9666-9679.	1.8	33
57	A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients. <i>Blood</i> , 2008, 112, 652-652.	1.4	33
58	Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans. <i>British Journal of Haematology</i> , 2007, 136, 729-735.	2.5	32
59	Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. <i>Cancer</i> , 2019, 125, 750-760.	4.1	31
60	Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. <i>Blood Cancer Journal</i> , 2021, 11, 106.	6.2	31
61	Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. <i>The Hematology Journal</i> , 2004, 5, 312-317.	1.4	30
62	Thalidomide+dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide+dexamethasone: a case-matched study in advanced multiple myeloma. <i>European Journal of Haematology</i> , 2007, 78, 297-302.	2.2	30
63	Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. <i>Haematologica</i> , 2020, 105, 193-200.	3.5	29
64	Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1026-1032.	2.0	28
65	Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide. <i>Leukemia and Lymphoma</i> , 2011, 52, 776-785.	1.3	27
66	Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. <i>Journal of Hematology and Oncology</i> , 2019, 12, 4.	17.0	27
67	Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 2401-2415.	4.3	26
68	Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study. <i>Stem Cell Research and Therapy</i> , 2015, 6, 64.	5.5	25
69	Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 27-35.	4.4	25
70	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3613-3622.	1.6	25
71	Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide- Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2008, 112, 158-158.	1.4	25
72	Bortezomib Plus Dexamethasone Followed by Escalating Donor Lymphocyte Infusions for Patients with Multiple Myeloma Relapsing or Progressing after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 424-428.	2.0	24

#	ARTICLE	IF	CITATIONS
73	Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. <i>American Journal of Hematology</i> , 2014, 89, 355-362.	4.1	24
74	High-dose daunorubicin as liposomal compound (Daunoxome®) in elderly patients with acute lymphoblastic leukemia. <i>The Hematology Journal</i> , 2003, 4, 47-53.	1.4	23
75	Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. <i>Haematologica</i> , 2019, 104, 1640-1647.	3.5	22
76	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. <i>European Journal of Haematology</i> , 2009, 82, 93-105.	2.2	21
77	Triplet vs. doublet drug regimens for managing multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 137-149.	1.8	21
78	ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with <i>de novo</i> multiple myeloma. <i>European Journal of Haematology</i> , 2010, 84, 474-483.	2.2	20
79	A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients. <i>Blood</i> , 2013, 122, 763-763.	1.4	20
80	Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study). <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2013-2018.	3.0	19
81	Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2011, 90, 1449-1456.	1.8	19
82	Pomalidomide for the treatment of relapsed/refractory multiple myeloma: a review of biological and clinical data. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 499-510.	2.4	19
83	Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. <i>American Journal of Hematology</i> , 2017, 92, 244-250.	4.1	19
84	Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1449-1462.	3.1	18
85	Primary plasma cell leukemia in the era of new drugs: Has something changed?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 141-149.	4.4	18
86	Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL). <i>Leukemia and Lymphoma</i> , 2005, 46, 233-238.	1.3	17
87	Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 619-634.	4.1	17
88	Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. <i>Haematologica</i> , 2020, 106, 291-294.	3.5	17
89	Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP). <i>Annals of Hematology</i> , 2021, 100, 429-436.	1.8	17
90	Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosphamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age. <i>Blood</i> , 2013, 122, 539-539.	1.4	17

#	ARTICLE	IF	CITATIONS
91	First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. <i>Haematologica</i> , 2020, 105, 1074-1080.	3.5	16
92	Novel Experimental Drugs for Treatment of Multiple Myeloma. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 245-264.	3.2	16
93	Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study. <i>Blood</i> , 2020, 136, 37-38.	1.4	16
94	Risk assessment of patients with hematologic malignancies who develop fever accompanied by pulmonary infiltrates. <i>Cancer</i> , 2004, 101, 567-577.	4.1	15
95	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. <i>Blood Cancer Journal</i> , 2020, 10, 40.	6.2	15
96	Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations. <i>European Journal of Haematology</i> , 2012, 89, 276-277.	2.2	14
97	Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the <scp>SEIFEM</scp> registry. <i>British Journal of Haematology</i> , 2015, 170, 434-439.	2.5	14
98	A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens.. <i>Blood</i> , 2009, 114, 492-492.	1.4	14
99	Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 9-16.	4.4	13
100	Bendamustine for the treatment of multiple myeloma in first-line and relapsed/refractory settings: a review of clinical trial data. <i>Leukemia and Lymphoma</i> , 2015, 56, 559-567.	1.3	12
101	Real-life analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1062-1068.	3.0	11
102	Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study. <i>Haematologica</i> , 2003, 88, 1432-3.	3.5	11
103	Mobilization-Driven Postconsolidation Therapy in Elderly Patients with Acute Myeloid Leukemia: Feasibility and Efficacy of Autologous Stem Cell Transplantation versus Low-Dose Gemtuzumab Ozogamicin. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1399-1406.	2.0	10
104	Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes. <i>Blood</i> , 2018, 132, 125-125.	1.4	10
105	Serum C-Reactive Protein at Diagnosis and Response to Therapy Is the Most Powerful Factor Predicting Outcome of Multiple Myeloma Treated with Thalidomide/Anthracycline-Based Therapy. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 294-299.	1.4	9
106	First-Line Treatment of Multiple Myeloma in Elderly Patients: the GIMEMA (Gruppo Italiano Malattie) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 10, 906-922.	2.1	9
107	How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 779-793.	4.1	9
108	Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. <i>Blood Cancer Journal</i> , 2020, 10, 58.	6.2	9

#	ARTICLE	IF	CITATIONS
109	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1357-1366.	2.5	8
110	Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?. <i>Cells</i> , 2022, 11, 606.	4.1	8
111	A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients. <i>Experimental Hematology</i> , 2007, 35, 1074-1082.	0.4	7
112	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. <i>Blood Cancer Journal</i> , 2021, 11, 73.	6.2	7
113	Oral ixazomib maintenance therapy in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 21-32.	2.4	6
114	Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1271-1273.	1.3	6
115	A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 127.	2.4	6
116	Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed myeloma patients: PFS1, PFS2, OS endpoints.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8515-8515.	1.6	6
117	Acycloguanosine for the treatment of aplastic anaemia. <i>European Journal of Haematology</i> , 1991, 46, 120-121.	2.2	5
118	Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 1657-1660.	1.3	5
119	A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma. <i>Future Oncology</i> , 2018, 14, 319-329.	2.4	5
120	Comparison of Two Regimens for the Treatment of Elderly Patients with Acute Lymphoblastic Leukaemia (ALL).. <i>Blood</i> , 2004, 104, 4490-4490.	1.4	5
121	Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study. <i>Blood</i> , 2014, 124, 2110-2110.	1.4	5
122	Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma: The Phase I/II EMN09 Study. <i>Blood</i> , 2016, 128, 3334-3334.	1.4	5
123	Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. <i>European Journal of Haematology</i> , 2022, 108, 178-189.	2.2	5
124	Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. <i>Blood Cancer Journal</i> , 2021, 11, 197.	6.2	5
125	Diagnostic value of C-reactive protein in discriminating fungal from nonfungal pulmonary infiltrates in patients with hematologic malignancies. <i>Supportive Care in Cancer</i> , 2006, 14, 874-877.	2.2	4
126	Outcome and Toxicity in the Modern Era of New Drugs for Multiple Myeloma: A Reappraisal for Comparison With Future Investigational Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 353-360.	0.4	4

#	ARTICLE	IF	CITATIONS
127	Introduction to "Immunotherapies for Multiple Myeloma". <i>Pharmaceuticals</i> , 2020, 13, 396.	3.8	4
128	Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment. <i>Pharmaceuticals</i> , 2020, 13, 426.	3.8	4
129	Developments in consolidation and maintenance strategies in post-remission multiple myeloma. <i>Expert Review of Hematology</i> , 2020, 13, 351-362.	2.2	4
130	Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103203.	4.4	4
131	Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. <i>Cancer</i> , 2021, 127, 3413-3421.	4.1	4
132	Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study. <i>Leukemia and Lymphoma</i> , 2010, 51, 1444-14449.	1.3	3
133	Smoldering multiple myeloma: to treat or not to treat. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 785-790.	1.8	3
134	Renal failure in multiple myeloma: something new on the horizon. <i>British Journal of Haematology</i> , 2017, 176, 845-846.	2.5	3
135	Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 289-295.	2.2	2
136	Anticoagulation and Vessel Recanalization in Cirrhotic Patients with Splanchnic Vein Thrombosis: A Multidisciplinary "Real Life" Experience. <i>Vascular Health and Risk Management</i> , 2021, Volume 17, 619-629.	2.3	2
137	Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 3126-3126.	1.4	2
138	Stem Cell Transplantation in Multiple Myeloma. <i>Current Cancer Drug Targets</i> , 2017, 17, 769-781.	1.6	2
139	An update on novel multiple myeloma targets. <i>Expert Review of Hematology</i> , 2022, 15, 519-537.	2.2	1
140	New Combination Approaches for Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S42-S43.	1.4	0
141	Risk Stratification in Newly Diagnosed Transplant Ineligible Multiple Myeloma. , 2018, , 37-58.		0
142	Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials. <i>Blood</i> , 2018, 132, 2023-2023.	1.4	0
143	Response to BNT162b2 Sars-Cov-2 Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2021, 138, 4871-4871.	1.4	0